Summary
Twenty-nine adult patients with primary myelodysplastic syndromes (MDS) and an excess of marrow blasts were treated by aggressive chemotherapy while still in MDS phase (20 cases) or after progression to ANLL (9 cases). Median age was 47.5 (range 18–68). Twenty-eight patients received a combination of Rubidazone and Ara C and 1 received High dose Ara C. Fourteen patients (48%) achieved complete remission (CR), 5 (17%) were treatment failures (F) and 10 (35%) died during therapy induced aplasia (DA). Median disease free survival was 8.5 months. Median survival of the whole population was 6 months from the onset of treatment, and 17 months in patients achieving CR. These results were significantly less favorable than those obtained at our institution in de novo ANLL with the same chemotherapy regimens. No statistically significant prognostic factors of treatment outcome emerged but patients with normal cytogenetic findings seemed to have both a higher CR rate and longer remissions than patients with abnormal karyotypes. Patients under 50 did not have higher CR rates than older patients, although they had longer remissions (with 3 out of 6 CRs exceeding 2 years). Finally, treatment outcome and survival were identical in patients treated in the MDS phase and in those treated after progression to ANLL. Combination chemotherapy is a highly toxic approach in MDS and essentially seems to benefit younger patients with a normal karyotype, in whom some long remissions can be obtained.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Appelbaum FR, Storb B, Ramberg RE, Shulman HM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Sanders J, Self S, Swiger J, Stewart P, Sullivan K, Witherspoon R, Thomas ED (1987) Treatment of preleukemic syndromes with marrow transplantation. Blood 69: 92–96
Armitage JO, Dick FR, Needlman SW, Burns CP (1981) Effect of chemotherapy for the myelodysplastic syndrome. Cancer Treat Rep 65: 601–605
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick M, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br Haematol 51: 189–199
Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low dose Ara C in patients with acute non lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–64
Fenaux P, Jouet JP, Zandecki M, Laï JL, Simon M, Pollet JP, Bauters F (1987) Chronic and subacute myelomonocytic leukemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol 65: 101–106
Gale RP, Foon KA (1987) Acute myeloid leukemia: recent advances in therapy. Blood 69: 1551–1562
ICSN (1978) An international system for human cytogenetic nomenclature. Cytogenet Cells Genet 21: 309–404
Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia by a combination of Rubidazone and Cytosine Arabinoside. Vincristine and Prednisone (ROAP). Blood 58: 584–591
Mertelsmann R, Thaler HT, To L, Gee TS, McKenzie S, Schaver P, Friedman A, Azlin Z, Cirrincione C, Clarkson B (1980) Morphological classification, response to therapy and survival in 263 adult patients with acute non lymphoblastic leukemia. Blood 56: 773–781
Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425–433
Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Brewman G, Walker I, Grünwald H, D'Arrigo P, Stein A, Bloom M, Goldberg J, Gottlieb A, Bennett J, Kersher J, Priore R (1986) High dose cytosine arabinoside in the treatment of preleukemic disorders. Am J Hematol 23: 131–134
Ruutu P, Ruutu T, Repo H (1981) Defective neutrophil migration in monosomy 7. Blood 58: 739–745
Scoazec JY, Imbert M, Crofts M, Jouault H, Sultan C (1985) Myelodysplastic syndrome or acute myeloid leukemia: a study of 28 cases presenting with borderline features. Cancer 55: 2390–2394
Spriggs DR, Stone RM, Kufe DM (1986) The treatment of myelodysplastic syndromes. Clin Haematol 15: 1081–1107
Tallman MS, Appelbaum FR, Amos D, Goldberg RS, Livingston RB, Mortimer J, Werden PL, Thomas ED (1987) Evaluation of intensive postremission chemotherapy for adults with acute non lymphocytic leukemia using high dose Cytosine Arabinoside with L asparaginase and Amsacrine with etoposide. J Clin Oncol 5: 918–926
Tricot G, Boogaerts MA (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63: 477–483
Vadhan-Ray S, Keating M, Lemaistre A, Hittelman WN, McCredie K, Twjillo JM, Broxmeyer HE, Henney C, Gutterman GU (1987) Effects of recombinant human granulocyte-macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545, 1552
Yunis JJ, Brunning RD (1986) Prognostic significance of chromosomal abnormalities in acute leukemias and myelodysplastic syndromes. Clin Haematol 15: 597–620
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fenaux, P., Lai, J.L., Jouet, J.P. et al. Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57, 297–302 (1988). https://doi.org/10.1007/BF00320357
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320357